A team of investigators sought to determine the prevalence of proton pump inhibitor-partial response gastroesophageal reflux disease in patients with systemic sclerosis.
The FDA has granted Orphan Drug designation to TMB-003 (Timber Pharmaceuticals) for the treatment of systemic sclerosis.
Researchers evaluated obstetric complications in women with a systemic sclerosis diagnosis vs the general obstetric population.
The performance of 5 core set measure in ACR-CRISS in recent trials was explored, and their ability to discern the active medication group from placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), was assessed.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
In this open-label extension study, researchers reported on the safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis.
Study authors analyzed the effects of nintedanib on changes in forced vital capacity and other measures of progression in systemic sclerosis-associated interstitial lung disease.
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
The British Society for Rheumatology released consensus-based recommendations for the management of juvenile systemic sclerosis.
Study authors determined the performance of pulmonary screening vs HRCT in detecting interstitial lung disease in juvenile SSc.